MAP2K7 and familial pancreatic carcinoma: A notable clinical trial for advanced pancreatic cancers is assessing rigosertib, which blocks RAS from associating with the RAS-binding domain of RAF, thereby preventing RAF/MEK/ERK signaling [25].